
GH Research PLC (NASDAQ:GHRS – Free Report) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of GH Research in a report issued on Tuesday, November 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($1.00) for the year, up from their previous forecast of ($1.14). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for GH Research’s Q4 2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.37) EPS, Q4 2027 earnings at ($0.47) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.70) EPS, FY2029 earnings at ($1.90) EPS and FY2030 earnings at ($0.40) EPS.
A number of other analysts have also recently issued reports on GHRS. Stifel Nicolaus set a $38.00 target price on shares of GH Research in a research note on Friday, November 13th. Wells Fargo & Company began coverage on shares of GH Research in a research note on Monday, July 27th. They issued an “overweight” rating and a $44.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research note on Thursday, October 15th. Guggenheim increased their price target on shares of GH Research from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald raised their price objective on shares of GH Research from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, GH Research presently has an average rating of “Moderate Buy” and an average target price of $44.00.
Read Our Latest Stock Analysis on GH Research
GH Research Price Performance
Shares of GHRS opened at $18.25 on Thursday. The firm has a market capitalization of $1.25 billion, a PE ratio of -19.21 and a beta of 1.31. The company’s 50-day moving average is $21.73 and its 200-day moving average is $21.68. GH Research has a fifty-two week low of $12.04 and a fifty-two week high of $31.44.
GH Research (NASDAQ:GHRS – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GHRS. Troluce Capital Advisors LLC grew its holdings in GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after buying an additional 617,260 shares in the last quarter. Braidwell LP bought a new position in GH Research during the 2nd quarter worth $5,571,000. Marshall Wace LLP lifted its holdings in shares of GH Research by 46.3% during the third quarter. Marshall Wace LLP now owns 68,298 shares of the company’s stock worth $1,604,000 after buying an additional 21,601 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of GH Research during the first quarter worth $290,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of GH Research during the second quarter worth $495,000. 56.90% of the stock is owned by institutional investors and hedge funds.
Key Stories Impacting GH Research
Here are a few of the latest stories about GHRS:
- Positive Sentiment: HC Wainwright revised several forecasts to project smaller losses, including FY2026 EPS of ($1.00), improved from ($1.14), and FY2030 EPS of ($0.40), up from ($1.22). It maintained its Buy rating and $55 target. HC Wainwright analyst information
- Positive Sentiment: Guggenheim raised its price target to $46 from $40 and kept a Buy rating, signaling continued confidence in the shares. Guggenheim analyst information
- Negative Sentiment: A report linked GH Research’s shares’ recent weakness to an analyst downgrade; the provided report does not identify the analyst or give further details. GH Research shares down on analyst downgrade
About GH Research
GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.
Featured Stories
- Five stocks we like better than GH Research
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
